Glutathione peroxidase 7 suppresses cancer cell growth and is hypermethylated in gastric cancer

Zheng Chen¹, Tianling Hu¹, Shoumin Zhu¹, Kenichi Mukaišho⁵, Wael El-Rifai¹,²,³,⁴ and Dun-Fa Peng¹

¹Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
²Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
³Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA
⁴Department of Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, USA
⁵Department of Pathology, Division of Molecular Diagnostic Pathology, Shiga University of Medical Science, Otsu, Shiga, Japan

Correspondence to: Dun-Fa Peng email: dunfa.peng@Vanderbilt.edu

Keywords: GPX7, stomach, cancer, DNA methylation, tumor suppressor

Received: March 17, 2017 Accepted: April 14, 2017 Published: April 29, 2017

Copyright: Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Gastric cancer (GC) is one of the most common cancers in the world, and remains the third leading cause of cancer-related deaths worldwide. Glutathione peroxidase 7 (GPX7) is a member of GPX family which is downregulated in some cancer types. In this study, we investigated the expression, regulation, and molecular function of GPX7 in gastric cancer using 2D and 3D in vitro models and de-identified human tissue samples. Quantitative real-time RT-PCR, immunofluorescence, Western blot, 3D organotypic cultures, and pyrosequencing assays were used. We detected downregulation of GPX7 in all 7 gastric cancer cell lines that we tested and in approximately half (22/45) of human gastric cancer samples, as compared to histologically normal gastric tissues. Quantitative bisulfite pyrosequencing methylation analysis demonstrated DNA hypermethylation (>10% methylation level) of GPX7 promoter in all 7 gastric cancer cell lines and in 56% (25/45) of gastric cancer samples, as compared to only 13% (6/45) in normal samples (p < 0.0001). Treatment of AGS and SNU1 cells with 5-Aza-2′-deoxycytidine led to a significant demethylation of GPX7 promoter and restored the expression of GPX7. In vitro assays showed that reconstitution of GPX7 significantly suppressed gastric cancer cell growth in both 2D and 3D organotypic cell culture models. This growth suppression was associated with inhibition of cell proliferation and induction of cell death. We detected significant upregulation of p27 and cleaved PARP and downregulation of Cyclin D1 upon reconstitution of GPX7. Taken together, we conclude that epigenetic silencing of GPX7 could play an important role in gastric tumorigenesis and progression.

INTRODUCTION

Gastric cancer (GC) is one of the most common cancers in the world [1–3], and remains the third leading cause of cancer-related deaths worldwide [3]. Although there has been a decline in the overall incidence of distal gastric cancer during the past decades, the incidence is rising for adenocarcinomas of the proximal part of the stomach in the Western world [2]. Helicobacter pylori (H. pylori) infection is very common in the populations with high incidence of gastric cancer, for example, in Eastern Asia. H. pylori infection has been linked with gastric tumorigenesis through a multistep pathogenesis cascade [4–7]. Accumulating data indicate that H. pylori infection and subsequent induction of gastritis generate high levels of reactive oxygen species (ROS) [8, 9]. ROS induces DNA damage in gastric epithelial cells and contributes to gastric carcinogenesis [10, 11]. Moreover, H. pylori-induced ROS in gastric epithelial cells may be involved in activation of oncogenic signal transduction pathways that mediate gastric carcinogenesis [12–14].
Normal cells have intact antioxidant properties that protect them from ROS-induced DNA damage and cell injury [15, 16]. Among these systems, the glutathione peroxidase family (GPXs) is a major antioxidant enzyme family that catalyzes the reduction of hydrogen peroxide, organic hydroperoxide, and lipid peroxides by reduced glutathione [17–20]. Glutathione peroxidase 7 (GPX7), is a relatively recent member of the glutathione peroxidase family, a non-selenocysteine containing phospholipid hydroperoxide glutathione peroxidase (NPGPx) [21]. It has been previously reported that GPX7 can protect esophageal cells from acidic bile acids-induced ROS generation, oxidative stress and oxidative DNA damage [22]. However, the levels and roles of GPX7 in gastric tumorigenesis have not been elucidated. In the present study, we examined GPX7 gene expression, promoter methylation status, and its potential function in suppressing growth of gastric cancer cells.

RESULTS

GPX7 expression is silenced with promoter hypermethylation in gastric cancer cell lines

To examine GPX7 gene expression in gastric cancers, we first carried out a quantitative real-time reverse transcription PCR (qRT-PCR) analysis of mRNA expression in 7 gastric cancer cell lines. Surprisingly, GPX7 mRNA expression was not detectable (completely silenced) in all 7 gastric cancer cell lines examined whereas a normal gastric tissue sample displayed strong GPX7 expression, visualized using gel electrophoresis in Figure 1A. We confirmed silencing of GPX7 protein expression using Western blot analysis (Figure 1B). Because GPX7 promoter has a large CpG island (Figure 1C), we investigated the GPX7 promoter hypermethylation as a cause of GPX7 downregulation in gastric cancers. Using pyrosequencing technology (Figure 1D, 1E and 1F), we quantitatively analyzed GPX7 promoter DNA methylation in all cancer cell lines. We found that GPX7 promoter region is highly hypermethylated in all gastric cancer cell lines that we tested, showing high DNA methylation levels of all tested CpG nucleotides (range 50%–100%) (Figure 1F).

GPX7 is downregulated and hypermethylated in primary gastric cancers

Next, we checked GPX7 mRNA expression in 45 paired gastric cancer tissue samples and corresponding histologically normal adjacent tissue samples. We found that 22 out of 45 (48.8%) primary gastric cancers showed a significant downregulation of GPX7 as compared to their normal adjacent samples (Figure 2A). These results suggest that dysfunction of GPX7 is a frequent event in gastric cancers. Using pyrosequencing, we quantitated GPX7 promoter methylation level in these gastric cancers and their matched normal samples. Figure 2B displays the pyrosequencing profile in each CpG site examined in two representative normal and tumor samples. We detected GPX7 promoter hypermethylation (> 10% DNA methylation level) in 55.6% (25/45) of tumor tissue samples (range: 11%–65%) while only 13.3% (6/45) of normal gastric tissues showed > 10% methylation levels (range: 11%–24%) (Fisher exact test, p < 0.0001, Table 1). Overall, the DNA methylation level was significantly higher in gastric cancers than that in normal tissues (p < 0.001, Figure 2C). Figure 2D displays the DNA methylation level change in paired individual tumor and adjacent normal gastric mucosae (p < 0.001).

Promoter DNA hypermethylation of the GPX7 gene correlates with downregulation of mRNA expression

We next analyzed the promoter DNA methylation against mRNA expression levels in all samples. Samples with DNA hypermethylation (> 10%) had significant lower levels of GPX7 expression than samples with DNA unmethylation (≤ 10%) (Supplementary Figure 1, p = 0.01). Using the Spearman rank correlation, we found a significant inverse correlation between promoter methylation and mRNA expression of GPX7 (coefficient r = −0.27, p = 0.01; Figure 2E). These results suggest that the hypermethylation of the GPX7 promoter correlates to the suppression of its mRNA expression in gastric cancers.

5-Aza-2′ Deoxycytidine (5-Aza) and Trichostatin-A (TSA) treatments restored GPX7 expression in gastric cancer cell lines

To confirm that GPX7 is silenced by an epigenetic molecular mechanism, we treated AGS and SNU1 cancer cells (GPX7 is silenced in both cell lines) with 5-Aza (a DNA methyltransferase) alone or in combination with TSA (a histone deacetylase inhibitor). As shown in Figure 2F (AGS cells) and 2G (SNU1 cells), the 5-Aza treatment alone or in combination with TSA restored GPX7 mRNA expression in both cell lines, and this restoration of gene expression was associated with promoter demethylation.

Reconstitution of GPX7 suppresses growth of gastric cancer cells

An earlier study has shown that GPX7 has potential tumor suppressor functions in esophageal adenocarcinoma [23]. We, therefore, tested the effect of GPX7 reconstitution on gastric cancer cells (AGS and MKN45) using colony formation and 3D organotypic culture assays. As shown, reconstitution of GPX7 led to a significant inhibition of cancer cell growth, as measured by colony formation assay (AGS, Figure 3A and 3B; MKN45, 54346 Oncotarget
We have found that MKN45 cells grow well in 3D organotypic cultures; we therefore used this cell line for testing the effects of GPX7 reconstitution on tumor growth in 3D model. As shown, the MKN45 control cells (Ad-ctrl) grew well and formed several layers of tumor growth at 2 weeks, which strongly mimicked that in vivo tumor growth conditions. On the contrary, the MKN45 cells failed to grow and form tumor layers following reconstitution of GPX7 (Ad-GPX7) (Figure 3E).

Reconstitution of GPX7 suppresses cancer cells’ proliferation and impairs the expression of cell cycle regulators

To explore the potential mechanism for the suppression of gastric cancer cell growth, we first checked if GPX7 has an effect on cell proliferation of gastric cancer cells. We performed an EdU incorporation assay, which measures active DNA synthesis. AGS cells

Figure 1: GPX7 is silenced and hypermethylated in gastric cancer cell lines. (A) qRT-PCR analysis of GPX7 gene expression in 7 gastric cancer cell lines and a normal gastric mucosa sample, showing undetectable GPX7 mRNA in all 7 gastric cancer cell lines examined. (B) Western blotting analysis of GPX7 protein in the 7 gastric cancer cell lines. (C) A schematic drawing shows a CpG island in GPX7 gene promoter, and pyrosequencing assay location. Each vertical bar represents a CpG site. TSS, transcription start site. DNA methylation level of 8 CpG sites in the GPX7 promoter was quantitated by pyrosequencing. (D) and (E) show representative pyrosequencing profiles of AGS and a normal gastric mucosa sample respectively. (F) Displays DNA methylation level of GPX7 promoter in the 7 gastric cancer cell lines, showing more than 50% methylation level in all the cell lines.
Figure 2: **GPX7 is downregulated and hypermethylated in primary gastric cancers.** (A) Downregulation of the GPX7 gene expression was found in 48.8% primary gastric cancer samples as compared to their matched normal samples from the same patients. (B) A schematic profile shows GPX7 methylation of the 8 CpG sites in 2 representative matched normal (NG) and tumor (T) samples. (C) Shows the average DNA methylation level of GPX7 promoter in 45 normal and 45 tumor samples. ***p < 0.001. (D) The DNA methylation level change of GPX7 promoter in 45 individual matched normal and tumor samples from the same patients is indicated (p < 0.001). (E) The Spearman rank correlation analysis between GPX7 promoter methylation and gene expression in all the samples, displays a reverse correlation between DNA methylation and gene expression (r = −0.27, p = 0.01). (F) and (G) show GPX7 gene expression and promoter methylation after 5-aza and/or TSA treatment in AGS (F) and SNU1 (G) cells. Relative GPX7 expression folds are shown in the right panels. DNA methylation levels of corresponding samples are shown on the left panels. 5-Aza, 5-Aza-2’ deoxycytidine. TSA, Trichostatin-A. DMSO, Dimethyl Sulfoxide. *p < 0.05, **p < 0.01, ***p < 0.001, as compared to DMSO control.
Table 1: Frequency of DNA hypermethylation in gastric cancers and their matched normal samples

|            | Unmethylated | Methylated |
|------------|--------------|------------|
| Normal     | 39           | 6          |
| Tumor      | 20           | 25         |

DNA methylation level was determined by pyrosequencing. If the average DNA methylation level > 10%, it was classified as methylated, otherwise it was classified as unmethylated. Fisher exact test, $p < 0.0001$.

Figure 3: Reconstitution of GPX7 suppressed tumor cells growth. (A) and (B) Colony formation assay in AGS. Panel (B) shows quantitative data of (A) (***$p < 0.001$). (C) and (D) Colony formation assay in MKN45. Panel (D) shows quantitative data of (C) (*$p < 0.05$). (E) Organotypic 3D cell culture using MKN45 cells. Cells were harvested at day 4, 7 and 14. Results show HE staining of cells and display 3D (3-dimensional) structure. Tumor cells with GPX7 expression (Ad-GPX7) grew on the 3D culture at the beginning, but became much thinner at 1 week and finally died after 2 weeks, while control cells (Ad-ctrl) grew to form multiple layers at 2 weeks.
were infected with Ad-Ctrl and Ad-GPX7. 48 hours after viral infection, EdU assay was performed. As shown in Figure 4A and 4B, cells with GPX7 expression (Ad-GPX7) displayed significantly lower positive rate for EdU as compared to Ad-Ctrl ($p < 0.001$), indicating that GPX7-expressing cells have lower cell proliferation rate. We also examined gene expression of p27 and Cyclin D1, using immunocytochemistry at the same 48 hour time point, we found that GPX7-expressing cells (Ad-GPX7) expressed higher level of p27 (Figure 4C and 4D) and lower level of Cyclin D1 (Figure 4E and 4F). To confirm the above results, we carried out an immunofluorescence staining of Ki67, p27 and Cyclin D1 in our 3D organotypic culture model. As shown in Figure 5, cells with Ad-GPX7 expression in 3D culture showed significantly lower Ki67 positive rate (Figure 5A and 5B, $p < 0.001$), higher p27 expression (Figure 5C and 5D, $p < 0.01$) and lower Cyclin D1 expression (Figure 5E and 5F, $p < 0.05$), in consistent with the 2D cell culture.

Reconstitution of GPX7 in gastric cancer cells induced cell death

To determine if GPX7 can regulate cell death and contribute to suppression of gastric cancer cell growth, AGS cells were infected with control (Ad-Ctrl) and GPX7 (Ad-GPX7) adenovirus particles. We did not observe significant changes in cell morphology within 48 hours after infection. However, GPX7 expressing cells started to float at 72 hours and majority of cells were floating after six days (Figure 6A). Trypan blue assay confirmed that the floating cells were dead cells (Figure 6B). A similar observation was obtained with MKN45 cells (Supplementary Figure 2). Flow cytometry analysis of Annexin V showed that GPX7 expressing cells had a higher rate of Annexin V positive cells, as compared to control cells (Figure 6C, $p < 0.05$). To confirm this result, we carried out Western blotting analysis for cleaved PARP, a marker of apoptosis. As shown in Figure 6D, cells with reconstitution of GPX7 expression in AGS and MKN45 displayed significantly higher levels of cleaved PARP than control cells.

DISCUSSION

The glutathione peroxidase family (GPXs) is a major antioxidant enzyme family that catalyzes the reduction of hydrogen peroxide, organic hydroperoxide, and lipid peroxides [17–20]. Therefore, GPXs’ function is important in counteracting ROS-induced oxidative DNA damage and protecting cells from DNA damage [22, 24]. In our previous study, we reported that GPX3, a secreted form of the GPX family that is readily detectable in plasma and mucosal surfaces [18, 24], is significantly downregulated in gastric cancers [25]. Here, we show that another GPX family member, GPX7 is also frequently silenced/
Figure 4: Reconstitution of GPX7 suppressed tumor cells proliferation in 2D culture. (A) EdU proliferation assay using AGS cells. Data shows GPX7-expressing cells (Ad-GPX7) had significantly lower EdU positive rate, meaning lower proliferation rate as compared to control cells (Ad-Ctrl). Right panel (B) shows quantitative data (**p < 0.001). (C) Immunocytochemistry staining of p27 protein using fluorescence. Data shows that GPX7-expressing cells (Ad-GPX7) had significantly higher p27 expression than control cells (Ad-Ctrl). Right panel (D) displays quantitative data (*p < 0.05). (E) Immunocytochemistry staining of Cyclin D1 protein using fluorescence. Data shows that GPX7-expressing cells (Ad-GPX7) had significantly lower Cyclin D1 expression as compared to control cells (Ad-Ctrl). Right panel (F) displays quantitative data (**p < 0.001).

Figure 5: Reconstitution of GPX7 suppressed cancer cells proliferation in 3D organotypic culture. (A) Immunocytochemistry staining of Ki67 protein using fluorescence. Data shows that GPX7-expressing cells (Ad-GPX7) had significantly lower Ki67 expression as compared to control cells (Ad-Ctrl). Right panel (B) displays quantitative data (**p < 0.001). (C) Immunocytochemistry staining of p27 protein using fluorescence. Data shows that GPX7-expressing cells (Ad-GPX7) had significantly higher p27 expression as compared to control cells (Ad-Ctrl). Right panel (D) displays quantitative data (**p < 0.01). (E) Immunocytochemistry staining of Cyclin D1 protein using fluorescence. Data shows that GPX7-expressing cells (Ad-GPX7) had significantly lower Cyclin D1 expression as compared to control cells (Ad-Ctrl). Right panel (F) displays quantitative data (*p < 0.05). (G) and (H) show the HE images of organotypic culture corresponding to the fluorescence images.
blue and Annexin V assays. This is evidenced in our 3D culture, in which tumor cells with GPX7 expression retarded to growth at Day 7 and finally died at Day 14 (Figure 3). Therefore, the cumulative negative impact of GPX7 on cancer cells includes not only reduction of their proliferative capacity, but also induction of cell death. However, there are multiple forms of non-apoptotic cell death [30, 31] that may also contribute to the net outcome and functions of GPX7 in cellular homeostasis.

In conclusion, our results suggest that GPX7 gene inactivation by promoter methylation is a frequent event in gastric cancer. Reconstitution of GPX7 in gastric cancer cells significantly suppressed tumor cell growth through inhibition of proliferative capacity and induction of cell death. Further studies are needed to explore the spectrum of functions of GPX7 and their underlying mechanisms in gastric tumorigenesis.

MATERIALS AND METHODS

Ethics statement

De-identified human tissue samples were obtained from the archives of pathology at Vanderbilt University (Nashville, TN USA) and from the National Cancer Institute Cooperative Human Tissue Network (CHTN). The use of specimens was approved by the Institutional Review Board at Vanderbilt University Medical Center. All patients provided written consent, and samples were collected after surgical resection. All tissue samples included in this study were collected from de-identified tissues that remained after the completion of diagnosis and are otherwise discarded.

Tissue samples

45 primary de-identified gastric cancer tissue samples and their matched adjacent normal gastric mucosae were collected in accordance with Vanderbilt Institutional Review Board approvals. All 45 tumors samples were histologically verified and their adjacent normal mucosae were histologically normal and tumor-free. The gastric adenocarcinomas included well-differentiated (WD), moderately-differentiated (MD) and poorly-differentiated (PD), stages from stage I to stage IV, with a mix of intestinal- and diffuse-type tumors.

Cell lines

Seven gastric cancer cell lines (AGS, MKN28, MKN45, MKN74, SNU1, SNU5, SNU16) were purchased from American Type Culture Collection (Manassas, VA USA http://www.atcc.org) or Riken (Ibaraki, Japan; http://www.brc.riken.go.jp/lab/cell/english). Cell lines were

Figure 6: Reconstitution of GPX7 induced cancer cells death. (A) Live cell images under an inverse microscope after reconstitution of GPX7 in AGS cells. Results show that tumor cells with GPX7 expression (Ad-GPX7) started to detach from the plate's bottom from day 3 of reconstitution of GPX7 and at day 6, most of the tumor cells were floating. (B) Trypan blue assay to count dead cells as well as viable cells. Data confirmed that the floating cells observed under microscope were dead cells. (C) Annexin V flow cytometry analysis of apoptosis. Data shows tumor cells with GPX7 expression (Ad-GPX7) displayed higher Annexin V cells ($p < 0.05$). (D) Western blot analyses of cleaved PARP in AGS and MKN45 cells. Results confirmed that cells with GPX7 expression had more cleaved PARP in both cell lines. The western blots with molecular marker is shown in Supplementary Figure 3.
DNA from cells and primary tissues was purified using a DNeasy Tissue Kit (Qiagen). An EZ DNA Methylation-Gold Kit (Zymo Research, Orange, CA USA) was used to do bisulfite modification of the DNA from cell lines and tissues, according to the manufacturer’s protocol. The GPX7 promoter CpG island was identified by using a CpG island online search tool (http://www.uscnorris.edu). The promoter region was amplified by PCR using Platinum PCR SuperMix High Fidelity Enzyme Mix (Invitrogen) as previously described [33]. The primers (forward 5′-AACTGTTGCTGAGAGAGAGA-3′ and reverse 5′-CCAACAGGCTGACAGGAGGAAGG-3′) were designed using the online software, Primer 3 (http://frodo.wi.mit.edu/). qRT-PCR was performed using an iCycler (Bio-Rad) with the threshold cycle number determined by use of iCycler software, version 3.0. Reactions were performed in triplicate and the threshold numbers were averaged. Results for the GPX7 gene were normalized to HPRT1 gene (forward 5′-TTGGAAAGGGTGTTATTCCTCA-3′ and reverse 5′-TCCACGAGGCTAGCAGGAAGGA-3′), which had minimal variation in all normal and tumor samples tested, and is therefore considered to be a reliable and stable reference gene for RT-PCR. Expression was calculated by use of the formula $2^{(Rt\text{-}Et)/2(Rn\text{-}Et)}$ as previously described [32, 33]. For all of the primary gastric carcinoma samples, the gene was considered downregulated if the relative mRNA expression was $\leq 0.6$, as compared to their matched normal samples.

**Quantitative real-time reverse transcription PCR (qRT-PCR) analysis of GPX7**

Total RNA was isolated using the RNeasy Mini-kit (Qiagen, Valencia, CA USA). Single-stranded cDNA was subsequently synthesized using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA USA). Expression of GPX7 was evaluated for 45 gastric carcinomas and their matched normal gastric mucosae adjacent to cancers. The GPX7 primers (forward 5′-AACTGTTGCTGAGAGAGGAAGG-3′ and reverse 5′-TTGGAAAGGGTGATTTCCTCA-3′) were designed using the online software, Primer 3 (http://frodo.wi.mit.edu/). qRT-PCR was performed using an iCycler (Bio-Rad) with the threshold cycle number determined by use of iCycler software, version 3.0. Reactions were performed in triplicate and the threshold numbers were averaged. Results for the GPX7 gene were normalized to HPRT1 gene (forward 5′-TTGGAAAGGGTGTTATTCCTCA-3′ and reverse 5′-TCCACGAGGCTAGCAGGAAGGA-3′), which had minimal variation in all normal and tumor samples tested, and is therefore considered to be a reliable and stable reference gene for RT-PCR. Expression was calculated by use of the formula $2^{(Rt\text{-}Et)/2(Rn\text{-}Et)}$ as previously described [32, 33]. For all of the primary gastric carcinoma samples, the gene was considered downregulated if the relative mRNA expression was $\leq 0.6$, as compared to their matched normal samples.

**DNA bisulfite treatment and pyrosequencing analysis**

DNA was used to bisulfite modification of the DNA from cell lines and tissues, according to the manufacturer’s protocol. The GPX7 promoter CpG island was identified by using a CpG island online search tool (http://www.uscnorris.edu), as previously described [33]. The pyrosequencing primers were designed using PSQ Assay Design Software (Qiagen) as previously described [33]. A 40 ng aliquot of modified DNA was amplified by polymerase chain reaction (PCR) of the specific promoter region using the Platinum PCR SuperMix High Fidelity Enzyme Mix (Invitrogen, Carlsbad, CA USA). The PCR products were checked by gel electrophoresis to confirm the size of the product and rule out the formation of primer dimers. Quantitative Pyrosequencing analysis of the specific PCR products was carried out using a Biotage PyroMark MD System (Qiagen), following the protocol provided by the manufacturer. The results were analyzed by Pyro Q-CpG 1.0.9 software (Qiagen). Based on the methylation levels in the normal samples, we used 10% methylation ($> 10\%$) as a cutoff for the identification of DNA hypermethylation of the GPX7 promoter. Statistical analysis was performed to detect significant changes in the frequencies of DNA methylation of the CpG sites between tumor and normal samples.

**5-Aza-2′ deoxycytidine treatment**

For validation of the role of promoter DNA hypermethylation in transcriptional regulation of GPX7 in vitro, gastric cancer cell lines AGS and SNU1 were used. Cells were seeded at low density for 24 hours and then treated with 5 μM 5-Aza-2′ deoxycytidine (5-Aza, Sigma-Aldrich, St. Louis, MO USA) for 72 hours and/or 300 nM Trichostatin-A (TSA, Wako, Osaka, Japan) for 24 hours. Total RNA and DNA were isolated and purified by RNeasy and DNeasy Tissue kits (Qiagen), as described above. DNA methylation levels of the CpG nucleotides of the GPX7 promoter were determined by Pyrosequencing. The GPX7 mRNA expression levels were determined by qRT-PCR, as described above.

**Construction of GPX7 expression adenoviral system**

A full length of GPX7 coding sequence with a synthetic Flag tag was amplified, from normal cDNA by PCR using Platinum PCR SuperMix High Fidelity (Invitrogen), and cloned into the pACCMV.pLP A plasmid [22]. The pACCMVP LP A-GPX7 plasmid was then co-transfected with pJM17 plasmid into 293 AD cells to generate and propagate the full adenoviral GPX7 particles, as previously described [22]. The viruses were plaque purified, and the titer of the virus was determined using the Adeno-X qPCR Titration Kit (Clontech, Mountain View, CA USA), following the manufacturer’s instructions.

** Colony formation assay**

AGS and MKN45 cells were infected with 5 MOI control (Ad-Ctrl) or GPX7 expression (Ad-GPX7) adenoviral particles. 24 hours after infection, cells were split and seeded in 6-well plates at 500 cells per well. Cells were cultured at 37°C for another 2 weeks. Cells then were stained with 0.05% crystal violet. The colonies were counted using ImageJ (National Institutes of Health) and data were analyzed using Prism software.

** Organotypic 3D culture**

Organotypic 3D reconstruct cultures were performed as previously described [34]. Briefly, human esophageal
fibroblasts (ScienCell, Carlsbad, CA USA) were seeded into a 3D matrix (75,000 cells/well) containing collagen I (High concentration rat tail collagen, Corning) and Matrigel (BD Biosciences, Franklin Lakes, NJ USA) and incubate for 7 days at 37°C. Following incubation, MKN45 cells infected with GPX7 expression (Ad-GPX7) or control (Ad-Ctrl) adenovirus particles (5 MOI each) were seeded (500,000 cells/well) on top of the fibroblast matrix. Cultures were then allowed to incubate for additional 4, 7 and 14 days. Cultures were harvested, fixed in 70% ethanol and processed at Vanderbilt University Medical Center Translational Pathology Shared Resource for embedding, HE staining and slides-cutting for immunocytochemistry.

Cell proliferation assay

To measure cell proliferation, the Click-iT EdU Assay (Invitrogen) was used as previously described [23, 35]. EdU (5-ethyl-2′-deoxyuridine) is a nucleoside analog of thymidine and is incorporated into DNA during active DNA synthesis. Therefore, it is an alternative to the BrdU assay. Briefly, AGS cells were infected with 5 MOI control or GPX7 expression adenoviral particles. The next day, 1 × 10⁴ cells per chamber were seeded on 8-chamber slides and incubated at 37°C for 24 hours. For labeling cells with EdU, equal volume of 2 × EdU solutions was added to the cells, and incubated at 37°C/5% CO₂ for 60 minutes. The cells were then fixed with 3.7% formaldehyde in PBS at room temperature for 15 minutes, followed by permeabilization with 0.5% Triton ×-100 in PBS for 20 minutes at room temperature. Click-iT reaction cocktail was then added to the cells and incubated for 30 minutes at room temperature, and protected from the light. Following removal of click-iT reaction cocktail, the cells were washed twice with 1 ml 3% BSA in PBS and Vectashield mounting medium with 4′,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Inc., Burlingame, CA USA) was added to the cells. EdU-positive cells (random fields at 40×, > 400 cells) were counted using ImageJ software. The percentage of EdU-positive cells versus total number of cells was calculated and statistically analyzed using Prism software.

Immunocytochemistry of cultured cells

AGS cells were infected with 5 MOI GPX7 expressing and control virus for 48 hours. The next day, the cells were seeded onto an 8-chamber culture slide. The second day, the cells were fixed with 4% paraformaldehyde in PBS at room temperature for 45 minutes, followed by permeabilization with 0.5% Triton ×-100 in PBS for 2 minutes on ice. After blocking, cells were incubated with primary antibodies (rabbit anti-p27 and mouse anti-Cyclin D1, 1:200 respectively, Cell Signaling, Danvers, MA USA) overnight at 4°C, and protected from the light. Cells were washed twice with PBS and incubated with anti-mouse or anti-rabbit secondary antibody labelled with Fluor-488 or Fluor-586 for 1 hour at room temperature, protected from light. After washing, cells were covered with Vectashield mounting medium with DAPI (Vector Laboratories). Cyclin D1 or p27-positive cells were counted (> 400 cells) using ImageJ software. The percentage of Cyclin D1 or p27-positive cells versus total number of cells was calculated and statistically analyzed using ImageJ software.

Immunocytochemistry of 3D organotypic cell culture

Paraffin-embedded 3D culture slides were deparaffined and rehydrated following standard protocols. Antigen retrieval was performed by boiling the slides into 1M Tris EDTA, pH8.0 for 10 min. Slides were allowed to cool down to room temperature before incubation in 5% BSA in PBS for 1 hour. Primary antibodies (anti-p27, anti-Cyclin D1 and anti-Ki67, 1:200, all from Cell Signaling) were added and slides were incubated overnight at 4°C in wet chambers. After washing with PBS, slides were incubated with anti-mouse or anti-rabbit secondary antibody with Fluor-488 or Fluor-586 labeling for 1 hour at room temperature, protected from light. Slides were mounted with Vectashield mounting medium with DAPI (Vector Laboratories). Images were examined and documented under an Olympus fluorescence microscope (Olympus BX41 with Olympus DP72 camera and CellSens Standard system, Olympus America Inc.). Positive cells were counted using ImageJ software. The percentage of positive cells was calculated and statistical analysis was performed.

Western blotting analysis

AGS and MKN45 cancer cells were infected with control (Ad-Ctrl) and GPX7 (Ad-GPX7) adenovirus particles (5 MOI) for 48 hours, then cells were lysed in the presence of proteinase inhibitor cocktail and phosphatase inhibitor (Santa Cruz Biotechnology, Dallas, TX USA). The protein concentration was determined by a Pierce BCA Protein Assay (Thermo Scientific, Rockford, IL USA) using a FLUOstar OPTIMA microplate reader (BMG Labtech, Cary, NC USA). Equal amount of proteins were loaded and separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes, and Western blot analysis was performed using standard protocols. The primary antibodies were: anti-GPX7 antibody (rabbit, 1:1000, Proteintech Group, Chicago, IL USA), and anti-PARP and cleaved PARP (Cell Signaling). A mouse monoclonal antibody against beta-actin (Sigma) was used as a loading control. Horseradish peroxidase-conjugated anti-mouse (1:10,000 dilution) and anti-rabbit (1:10,000 dilution)
secondary antibodies were purchased from Santa Cruz and Cell Signaling, respectively. Immunoreactive protein bands were documented using a Bio-Rad ChemiDoc XRST image system (Bio-Rad).

**Statistical analysis**

GraphPad Prism software version 4.0 (GraphPad Prism Software, La Jolla, CA USA) was used for statistical analyses. The Student t test was used to compare the DNA methylation level and mRNA ratios between normal and gastric cancers in matched samples (paired t-test) and unmatched samples (unpaired t-test). The correlation between the DNA methylation level and mRNA expression was determined by Spearman's rank correlation. The quantitative data were analyzed using student t test. All p values were based on two-tailed t-tests and differences were considered statistically significant when the p value was ≤0.05.

**Abbreviations**

GPX, glutathione peroxidase; MOI, Multiplicity of infection; DAPI, 4′,6-diamidino-2-phenylindole; 5-Aza, 5-Aza-2′ deoxycytidine; TSA, Trichostatin-A; EdU, 5-ethynyl-2′-deoxyuridine; qRT-PCR, quantitative real-time reverse transcription PCR; ROS, reactive oxygen species; GC, gastric cancer; DMSO, Dimethyl Sulfoxide.

**Authors’ contributions**

Z Chen, experimental design, execution and manuscript preparation; T Hu, DNA, RNA extraction, qRT-PCR, Pyrosequencing; S Zhu, experiments execution, K Mukaiasho, pathology evaluation; W El-Rifai, experimental design, trouble shooting, manuscript preparation, and funding. DF Peng, experimental design, execution, trouble shooting, manuscript preparation, and funding.

**ACKNOWLEDGMENTS**

We thank Dr. Holli Ann Loomans and Dr. Claudia D Andl for their assistance in setting up organotypic 3D cell culture. We thank Ms. Michele R Smith for assistance in editing the manuscript.

**CONFLICTS OF INTEREST**

No potential conflicts of interest were disclosed

**FUNDING**

The work was supported by CTSA award UL1TR000445 from the National Center for Advancing Translational Sciences (pilot grant VR2285, D. Peng), and National Institutes of Health (R01CA93999, W. El-Rifai) and Vanderbilt SPORE in Gastrointestinal Cancer (P50 CA95103), Vanderbilt Ingram Cancer Center (P30 CA68485), and the Vanderbilt Digestive Disease Research Center (DK058404) (W. El-Rifai). The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of National Institutes of Health, or Vanderbilt University Medical Center.

**REFERENCES**

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87–108.
2. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006; 12:354–362.
3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–386.
4. Pandey R, Misra V, Misra SP, Dwivedi M, Kumar A, Tiwari BK. Helicobacter pylori and gastric cancer. Asian Pac J Cancer Prev. 2010; 11:583–588.
5. Piazuelo MB, Epplein M, Correa P. Gastric cancer: an infectious disease. Infect Dis Clin North Am. 2010; 24:853–869, vii.
6. Pritchard DM, Crabtree JE. Helicobacter pylori pylori and gastric cancer. Curr Opin Gastroenterol. 2006; 22:620–625.
7. Zhang W, Lu H, Graham DY. An Update on Helicobacter pylori as the Cause of Gastric Cancer. Gastrointest Tumors. 2014; 1:155–165.
8. Augusto AC, Miguel F, Mendonca S, Pedrazzoli J Jr, Gurgueira SA. Oxidative stress expression status associated to Helicobacter pylori virulence in gastric diseases. Clin Biochem. 2007; 40:615–622.
9. Handa O, Naito Y, Yoshikawa T. Helicobacter pylori: a Redox biology and gastric carcinogenesis: the role of Helicobacter pylori. Biochem Pharmacol. 2007; 73:409–413.
10. Papa A, Danese S, Sgambaro A, Ardito R, Zannoni G, Rinelli A, Vecchio FM, Gentiloni-Silieri N, Cittadini A, Gasbarrini G, Gasbarrini A. Role of Helicobacter pylori CagA+ infection in determining oxidative DNA damage in gastric mucosa. Scand J Gastroenterol. 2002; 37:409–413.
11. Handa O, Naito Y, Yoshikawa T. Redox biology and gastric carcinogenesis: the role of Helicobacter pylori. Redox Rep. 2011; 16:1–7.
12. Handa O, Naito Y, Yoshikawa T. CagA protein of Helicobacter pylori: a hijacker of gastric epithelial cell signaling. Biochem Pharmacol. 2007; 73:1697–1702.
13. Smoot DT, Elliott TB, Verspaget HW, Jones D, Allen CR, Vernon KG, Brenner T, Kidd LC, Kim KS, Groupman JD, Ashktorab H. Influence of Helicobacter pylori on...
reactive oxygen-induced gastric epithelial cell injury. Carcinogenesis. 2000; 21:2091–2095.

14. Lamb A, Yang XD, Tsang YH, Li JD, Higashi H, Hatakeyama M, Peek RM, Blanke SR, Chen LF. Helicobacter pylori CagA activates NF-kappaB by targeting TAK1 for TRAF6-mediated Lys 63 ubiquitination. EMBO Rep. 2009; 10:1242–1249.

15. Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res. 1999; 31:261–272.

16. Tew KD, Townsend DM. Glutathione-s-transferases as determinants of cell survival and death. Antioxid Redox Signal. 2012; 17:1728–1737.

17. Brigelius-Flohe R, Kipp A. Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta. 2009; 1790:1555–1568.

18. Brigelius-Flohe R. Glutathione peroxidases and redox-regulated transcription factors. Biol Chem. 2006; 387:1329–1335.

19. Wingler K, Brigelius-Flohe R. Gastrointestinal glutathione peroxidase. Biofactors. 1999; 10:245–249.

20. Herbette S, Roeckel-Drevet P, Drevet JR. Seleno-independent glutathione peroxidases. More than simple antioxidant scavengers. FEBS J. 2007; 274:2163–2180.

21. Utomo A, Jiang X, Furuta S, Yun J, Levin DS, Wang YC, Desai KV, Green JE, Chen PL, Lee WH. Identification of a novel putative non-selenocysteine containing phospholipid hydroperoxide glutathione peroxidase (NPGPxs) essential for alleviating oxidative stress generated from polyunsaturated fatty acids in breast cancer cells. J Biol Chem. 2004; 279:43522–43529.

22. Peng D, Belkhiri A, Hu T, Chaturvedi R, Asim M, Wilson KT, Zaika A, El-Rifai W. Glutathione peroxidase 7 protects against oxidative DNA damage in oesophageal cells. Gut. 2012; 61:1250–1260.

23. Peng D, Hu T, Soutto M, Belkhiri A, Zaika A, El-Rifai W. Glutathione peroxidase 7 has potential tumour suppressor functions that are silenced by location-specific methylation in oesophageal adenocarcinoma. Gut. 2014; 63:540–551.

24. Brigelius-Flohe R, Maiorino M. Glutathione peroxidases. Biochim Biophys Acta. 2013; 1830:3289–3303.

25. Peng DF, Hu TL, Schneider BG, Chen Z, Xu ZK, El-Rifai W. Silencing of glutathione peroxidase 3 through DNA hypermethylation is associated with lymph node metastasis in gastric carcinomas. PLoS One. 2012; 7:e46214.

26. Kalabis J, Wong GS, Vega ME, Natsui-zaka M, Robertson ES, Herlyn M, Nakagawa H, Rustgi AK. Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture. Nat Protoc. 2012; 7:235–246.

27. Chioni AM, Bajwa RT, Grose R. 3D Organotypic Culture Model to Study Components of ERK Signaling. Methods Mol Biol. 2017; 1487:255–267.

28. Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008; 10:e19.

29. Roy A, Banerjee S. p27 and leukemia: cell cycle and beyond. J Cell Physiol. 2015; 230:504–509.

30. Tait SW, Ichim G, Green DR. Die another way—non-apoptotic mechanisms of cell death. J Cell Sci. 2014; 127:2135–2144.

31. Hildebrand JM, Sun L, Silke J. An appointment with death, : 2013 Cold Spring Harbor Asia meeting ‘mechanisms and functions of non-apoptotic cell death’. Cell Death Differ. 2013; 20:1593–1594.

32. El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ, Frierson HF Jr, Powell SM. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 2002; 62:6823–6826.

33. Peng DF, Razvi M, Chen H, Washington K, Roessner A, Schneider-Stock R, El-Rifai W. DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett’s adenocarcinoma. Gut. 2009; 58:5–15.

34. Le Bras GF, Loomans HA, Taylor CJ, Revetta FL, Andl CD. Activin A balance regulates epithelial invasiveness and tumorigenesis. Lab Invest. 2014; 94:1134–1146.

35. Vangamudi B, Peng DF, Cai Q, El-Rifai W, Zheng W, Belkhiri A. t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer. Mol Cancer. 2010; 9:240.